Inhibrx Inc

Inhibrx — Investor Presentation (March 2023)

47 slides from Inhibrx's investor presentation, Mar 6, 2023

  1. Slide 1: Outcomes Focused Innovation Driven March 2023

    Outcomes Focused Innovation Driven March 2023

  2. Slide 2: Presentation disclaimer

    2 Presentation disclaimer This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or o

  3. Slide 3: Why Inhibrx Should Be Front and Center on Your Radar

    3 Why Inhibrx Should Be Front and Center on Your Radar Four Biologic Programs in the Clinic All are demonstrating clinical activity with multi-billion-dollar potential peak sales. Two potentially registration-enabling programs are underway in 1H 2023. Our Interests are Aligned With Our Investors Cre

  4. Slide 4: Innovative Approach to Biologic Therapeutic Discovery & Development

    4 Innovative Approach to Biologic Therapeutic Discovery & Development Broad Internal Expertise + The modular nature of our platforms and technologies combined with our protein engineering expertise allow for rapid exploration of therapeutic approaches + Teams with deep biologics drug development exp

  5. Slide 5: INBRX-101 and INBRX-109 program highlights

    5 + No innovation for 30+ years and multiple recombinant AAT failures + Favorable safety and tolerability profile w/potential to achieve normal AAT levels with monthly dosing + Site activation and enrollment initiation for potentially registration-enabling trial expected in April 2023; Potential pat

  6. Slide 6: Other Programs on the Horizon

    6 Other Programs on the Horizon INBRX-101- GvHD Our Recombinant Alpha-1- Anti-trypsin Fc-Fusion Protein (AAT-Fc) Our Upcoming Therapeutic Candidates All potential best-in-class with differentiated profiles INBRX-121 Our NK cell targeted IL-2 + De-risked opportunity with promising clinical data with

  7. Slide 7: Partnerships with Industry Leaders

    7 PARTNER FOCUS CD47 checkpoint inhibitor Option to Ex-North America rights to INBRX-101 AATD Use of INBX sdAb platform for certain cell therapy products for up to 13 programs Merck-supplied Keytruda for INBRX-106 Phase 1 combo trial Joint venture with ArrowMark affiliate, Phylaxis Bioscience, LLC:

  8. Slide 8: Near Term Expected Clinical Milestones

    8 Near Term Expected Clinical Milestones 1H 2023 2H 2023 (DR5) Initial mesothelioma, Ewing sarcoma, pancreatic cancer, colorectal cancer and GIST combination study data (AATD) Start to potentially registration- enabling trial INBRX-101 INBRX-106 INBRX-101 (GvHD) Trial initiations for aGvHD and cGvHD

  9. Slide 9: INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein

    INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein

  10. Slide 10: INBRX-101 Alpha-1 Antitrypsin Deficiency (AATD)

    INBRX-101 Alpha-1 Antitrypsin Deficiency (AATD)

  11. Slide 11: Functional AAT Levels in Healthy Individuals vs. AATD Patients

    11 Functional AAT Levels in Healthy Individuals vs. AATD Patients Disease history + Alpha-1 antitrypsin deficiency (AATD) is an inherited orphan respiratory disease characterized by deficient levels of alpha-1 antitrypsin (AAT) + This causes loss of lung function and decreased life expectancy + A sm

  12. Slide 12: Current Standard of Care Does Not Maintain Normal AAT Levels

    12 Current Standard of Care Does Not Maintain Normal AAT Levels + INBRX-101, dosed every four weeks at 120 mg/kg, is predicted to maintain patients above the lower threshold of the normal range and achieve an average level (Cavg) of functional AAT that approximates that of healthy MM genotype adults

  13. Slide 13: Potential Advantages of Recombinant AAT Fc-fusion Protein

    13 Potential Advantages of Recombinant AAT Fc-fusion Protein AAT Fc Potential to extend the dosing interval from weekly to monthly Has demonstrated potential to maintain patients in normal functional AAT range Recombinant manufacturing provides abundant supply with no pathogen risk

  14. Slide 14: INBRX-101 Topline Results from Phase 1

    14 Complete INBRX-101 - Topline Results from Phase 1, Part 2 N=18 * bronchoalveolar lavage N=6 40 mg/kg N=6 80 mg/kg* N=6 120 mg/kg* INBRX-101 topline results – 3rd dose of 40, 80 or 120 mg/kg (Q3W) PART 2 Multiple ascending dose escalation (MAD) + Favorable safety and tolerability profile with only

  15. Slide 15: INBRX-101 is Present in the Lung in Every Patient Sampled

    15 INBRX-101 is Present in the Lung in Every Patient Sampled Following IV Dosing Bronchoalveolar lavage fluid (BALF) sample collection and analysis + BALF samples were collected from 3 lobes of the lung for each patient in the 80 (N = 5)1 and 120 (N = 6) mg/kg MAD cohorts prior to dosing and two wee

  16. Slide 16: INBRX-101 Potential ~$3B Annual U.S. Revenue in AATD

    16 INBRX-101 has the Potential to Achieve ~$3B in Annual U.S. Revenue with Expected Rapid Uptake in Patients with Severe AATD Notes: *Pricing assumption is for modelling purposes only Source: KOL Qualitative Interviews (n=~25); EvaluatePharma, Datamonitor, IQVIA, Fortune Business Insights, Analog an

  17. Slide 17: INBRX-101 Potential to Shift the Treatment Paradigm

    17 INBRX-101 has the Potential to Shift the Treatment Paradigm, Expanding Augmentation Therapy to a Broad Group of AATD Patients in the U.S. Sources: KOL Interviews, 1. Sandhaus Chronic Obstr Pulm Dis 2016; 2. Barjaktarevic and Miravitlles BMC Pulm Med 2021 TODAY FUTURE PI*ZZ or PI*SZ PI*ZZ or PI*SZ

  18. Slide 18: INBRX-101 Graft versus Host Disease (GvHD)

    INBRX-101 Graft versus Host Disease (GvHD)

  19. Slide 19: AAT and ruxolitinib data in GvHD

    19 Fred Hutch/Baxalta 1 Ph1/2 (n=12) U of Michigan/CSL 2 AAT +/- Prednisone Ph2 (n=40) Ef fic ac y ORR (%) at day 28 (per CIBMTR) 8/12 (67%) 26/40 (65%) CR (%) at day 28 4/12 (33%) 14/40 (35%) OS 6/12 alive 45% at 6 months Sa fe ty Grade 3+ AEs 0% 0% Most Frequent AEs “No clinical apparent toxicity

  20. Slide 20: INBRX-101 Potential in Acute GvHD

    20 INBRX-101 has the Potential for Fast Entry into Acute GVHD, Expanding to Prophylaxis, Achieving >$1bn in the US Market Sources: Qualitative research, third-party analysis, HRSA Blood Stem Cell (https://bloodstemcell.hrsa.gov/data) + TPP: Superior safety, efficacious in prophylaxis, same efficacy

  21. Slide 21: INBRX-101 GvHD Expansion Opportunities

    21 INBRX-101 GvHD Expansion Opportunities Sources: 1 2019 figures from HRSA Blood Stem Cell (https://bloodstemcell.hrsa.gov/data) 2 2017 figures for 40 European countries and 10 related countries: https://www.nature.com/articles/s41409-019-0465-9 3 2020 figures from JDCHCT https://drive.google.com/f

  22. Slide 22: INBRX-109 Tetravalent DR5 Agonist

    INBRX-109 Tetravalent DR5 Agonist

  23. Slide 23: A Next Generation DR5 Agonist

    23 A Next Generation DR5 Agonist with an Optimized Balance of Efficacy and Safety 1. Ashkenazi A, et al. J Clin Invest. 1999;104(2):155-162. 2. Walczak H, et al. Nat Med. 1999;5(2):157-163. 3. Valley CC et al. J Biol Chem. 2012;287(25):21265-21278. 4. Pan L, et al. Cell. 2019;176(6):1477-1489.e1414.

  24. Slide 24: Preliminary Phase 1 Data in Chondrosarcoma

    24 Preliminary Phase 1 Data in Unresectable or Metastatic Conventional Chondrosarcoma + Data cut point 8-Nov-2022, study ongoing + Response per RECISTv1.1 per Investigator assessment, data subject to change (e.g., some data raw and not verified) + PR=Partial Response, SD=Stable Disease, PD=Progressi

  25. Slide 25: INBRX-109 Phase 2 Registration-enabling Study Design

    25 ENDPOINTS Primary: Progression free survival Secondary: Overall survival, quality of life, overall response rate, duration of response, disease control rate, safety, etc. INBRX-109 Phase 2 Potentially Registration-enabling Study Design in Chondrosarcoma Randomization Conventional chondrosarcoma,

  26. Slide 26: Chondrosarcoma Prevalent Patient Pool

    26 Many Patients with Local Disease Eventually Progress to Unresectable or Metastatic Chondrosarcoma, Providing an Annual Prevalent Patient Pool of ~2.5K in the U.S. At Diagnosis Recurrence at 10 years Conventional chondrosarcoma Local (~75%) Low grade resectable (~55%) Metastatic (~25%) High grade

  27. Slide 27: INBRX-109 Potential ~$1B Annual Revenue

    27 Based on Current Trends and Lack of Approved Options, INBRX-109 has the Potential to Achieve ~$1B in Annual Revenue with Rapid Uptake Post Launch Notes: *Pricing assumption is for modelling purposes only based on analogous market research for oncology products in rare indications; Sources: KOL qu

  28. Slide 28: INBRX-109 on the Horizon

    28 INBRX-109 on the Horizon Combination studies Pancreatic adenocarcinoma 2nd line with mFOLFIRIN=20 Ewing sarcoma with Irinotecan + Temozolomide PART 3 Colorectal Cancer with FOLFIRI Data releases: 2H 2023 N=20 N=20 N=20 SDH-deficient GIST with Temozolomide Ongoing POTENTIAL FUTURE OPPORTUNITIES So

  29. Slide 29: INBRX-105 PD-L1 x 4-1BB Multispecific

    INBRX-105 PD-L1 x 4-1BB Multispecific

  30. Slide 30: Localizing and Potentiating the Anti-cancer Effects of the 4-1BB Pathway

    30  4-1BB (CD137/TNFRS9) is a member of the tumor necrosis factor (TNF) receptor superfamily and is an attractive target for immunotherapy due to its increased expression on tumor reactive TILs1  Agonistic 4-1BB mAbs have shown promising anti-tumor activity in early clinical studies2,3  However,

  31. Slide 31: INBRX-105 is a Potential Best-in-class 4-1BB Agonist

    31 INBRX-105 is a Potential Best-in-class 4-1BB Agonist CANDIDATE FORMAT 4-1BBL BLOCKING INBRX-105 Bivalent/Bivalent No Gen-1064 Monovalent/Monovalent n/a MCLA-145 Monovalent/Monovalent Yes FS222 Bivalent/Bivalent n/a PRS-343 Bivalent/Bivalent No ND021 Monovalent/Monovalent n/a CANDIDATE IGG SUBCLAS

  32. Slide 32: INBRX-105 Phase 1 Trial Design

    32 No pre-screening, all-comers N=30 No pre-screening, all-comers OngoingOngoingComplete INBRX-105 has the Potential to be the First 4-1BB Agonist with a Robust Therapeutic Window Single agent: PD-L1+ basket Single agent dose escalation Single agent dose expansion N=105-175N=38N=32 2H 2023 PART 2 PA

  33. Slide 33: INBRX-106 Hexavalent OX40 Agonist

    INBRX-106 Hexavalent OX40 Agonist

  34. Slide 34: INBRX-106 is a Potential Best-in-class OX40 Agonist

    35 INBRX-106 is a Potential Best-in-class OX40 Agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hexa- IgG1 N Ph 1 (2019) MOXR-0916 Bi- IgG1 Y Discontinued GSK-3174998 Discontinued BMS-986178 Ph 1 (2016) INCAGN-1949 Ph 1 (2016) ABBV-368 Ph 1 (HNSCC, 2020) IBI-101 Ph 1 (2018) MEDI-0

  35. Slide 35: Phase 1 INBRX-106 Trial Single Agent and with Keytruda

    36 OngoingComplete PART 1 Complete Complete PART 2 PART 4PART 3 Phase 1 INBRX-106 Trial as a Single Agent and in Combination with Keytruda® INBRX-106 single-agent dose escalation + 3+3 design + Locally advanced or metastatic solid tumors + All-comers Dose expansion with Keytruda Dose escalation with

  36. Slide 36: Potential Market Opportunity for INBRX-106 and INBRX-105

    37 Potential Market Opportunity for INBRX-106 and INBRX-105 The figures on this slide represent market research estimates from Evaluate Pharma *Keytruda and Opdivo® go off patent in 2028 $14.4 $7.9 $2.9 $2.0 $1.0 $28.2$27.1 $14.2 $7.4 $4.7 $10.1 $63.5 $0 $10 $20 $30 $40 $50 $60 $70 KEYTRUDA* OPDIVO*

  37. Slide 37: Cisleukin Platform

    CisleukinTM Platform A Targeted Cis-IL2 Platform

  38. Slide 38: Targeting the Anti-tumor Effects of IL-2

    39 Targeting the Robust Anti-tumor Effects of IL-2 to Overcome Off-target Toxicity  IL-2 is a potent stimulator of cytotoxic cell types with natural anti-tumor activity that has shown great promise as a single agent in multiple cancers1  However, efforts to mitigate the toxicities of IL-2 therapy

  39. Slide 39: INBRX-121 NK Cell Targeted Cisleukin Molecule

    INBRX-121 NK Cell Targeted CisleukinTM Molecule

  40. Slide 40: An NK Cell Targeted Cisleukin Molecule

    41 An NK Cell Targeted CisleukinTM Molecule + Natural Killer (NK) cells have potent cytolytic activity and are not limited by MHC-I presentation of tumor-associated antigens like T cells + NKp46 is an NK cell-specific marker that maintains expression on tumor-infiltrating NK cells + Targeting of aff

  41. Slide 41: INBRX-121 Poised to Bring NK Cells to the Forefront

    42 INBRX-121 INBRX-121 is poised to bring NK cells to the forefront of immunotherapy NK NK NK NK NK NK NK NK NK NK Improved NK Activity Safety with durability Single agent Activated NK cells exhibit immediate cytotoxicity Multiple potential paths forward Combination therapy Enhances the activity of

  42. Slide 42: Expanded mouse NK cells and enhanced cytotoxic potential

    43 Expanded mouse NK cells and enhanced their cytotoxic potential 0 2,000 3,000 4,000 5,000 KL RG 1 le ve ls 5,000 10,000 15,000 20,000 Gr an zy m e B le ve ls M ax . f ol d- ch an ge (r el at iv e to v eh ic le ) 0 5 10 20 25 15 NK cells CD8 T cells Tregs CD4+Tcon B cells NK cell cytolytic activity

  43. Slide 43: Synergized with approved therapeutic antibodies

    44 Synergized with approved therapeutic antibodies INBRX-121 synergized with Rituxan® in a subcutaneous Raji tumor model resulting in complete tumor regression Dosing Days TREATMENT COMPLETE RESPONSES Rituxan® 0/10 INBRX-121 + Rituxan® 9/10 Raji tumor growth 0 42 Time (days) 0 Tu m or Vo lu m e (m m

  44. Slide 44: INBRX-121 safely expanded NK cells in non-human primates

    45 INBRX-121 safely expanded NK cells in non-human primates 8% 82% 10% 41.5% 51.5% 7% Expanded NK cells in a dose-dependent manner (up to 12-fold) that persists for more than 21 days and can be dosed multiple times safely Tolerated in repeat dose range studies up to 10 mg/kg NK cell expansion in blo

  45. Slide 45: Expanded NK cells from Lymphoma patients

    46 Expanded NK cells from Lymphoma patients NK cells from Lymphoma patients expressed NKp46 at levels similar to or above that of healthy donors Patient NK cells responded to stimulation with INBRX-121 by upregulating pSTAT5 and showed an increased proliferative potential - + Healthy Donor 0 20 40 %

  46. Slide 46: Enhanced NK cytotoxic capacity against Raji cells

    47 Expanded the number of NK cells while enhancing their individual cytotoxic capacities INBRX-121 increased NK cell-mediated killing of Raji cells in the presence of a Rituximab sequence analog (Anti-hCD20- hIgG1). Raji cell killing after INBRX-121 pre-incubation Effector: target ratio 0 % Ta rge t

  47. Slide 47: Contact and Investor Relations

    11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com Investor Relations: Kelly Deck, CFO [email protected]

Inhibrx — Investor Presentation (March 2023) on 6ix